What it signals, what it doesn't, and how applicants should prepare now.
ARAC shared perspective with 2FIRSTS on FDA’s new pilot program for nicotine pouch PMTAs — and why the fundamentals still stand.
While the pilot aims to streamline review and allow some category-level data, the evidentiary bar hasn’t changed: applicants must still demonstrate that products are appropriate for the protection of public health through rigorous, product-specific data.
In short: faster doesn’t mean easier. Robust switching studies, clear marketing plans, and strong behavioral evidence remain essential to success — especially as FDA tests new pathways toward efficiency without compromising public health.
Sexy Scroll (by Baco): Custom